Generics BulletinAeon Biopharma, which is working on developing a biosimilar version of Botox (onabotulinumtoxinA) in the US, has looked to rival developer Revance Therapeutics to recruit its new chief executive. Aeon
Generics BulletinViatris has agreed to pay up to $335m as part of a nationwide settlement resolving US opioid-related claims by states and local governments, marking the latest monetary relief set to be owed by a comp
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Start-Up Nosis Partners Its AI Pl
Generics BulletinThe US Food and Drug Administration warning letter and import alert currently blocking export of seven of Viatris’ non-shortage-related products from its oral finished dose manufacturing facility in I